文献速递免疫规划传染病防控与疫情报告

接种BNT162b2疫苗加强针后及SARS-CoV-2奥密克戎感染后的抗体水平

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.
PubMed 文献 · Vaccine · 2022-08-26

本研究评估了61名已接种BNT162b2疫苗的医护人员在第二剂后270天内及加强针后90天内的免疫原性数据,比较了未感染与曾感染德尔塔和/或奥密克戎的医护人员。第二剂后270天抗体水平下降(p=0.0335),但未低于阳性阈值(33.8 BAU/ml);加强针后30天抗体水平上升(p=0.0486),随后在60和90天下降。14.7%的医护人员在加强针后感染奥密克戎,但均无严重症状。

要点

  • 第二剂BNT162b2疫苗后270天抗体水平下降(p=0.0335),但未低于阳性阈值33.8 BAU/ml。
  • 加强针后30天抗体水平上升(p=0.0486),随后60和90天下降。
  • 14.7%医护人员加强针后感染奥密克戎,均无严重症状。

核心结论

  • 加强针可显著提高抗体应答,但抗体水平随后随时间下降。

研究设计与样本

  • 研究纳入61名已接种BNT162b2疫苗的医护人员,分为未感染组和曾感染德尔塔和/或奥密克戎组,评估至第二剂后270天及加强针后90天的免疫原性数据。

主要发现

  • 第二剂后270天抗体水平下降(p=0.0335),但未低于阳性阈值33.8 BAU/ml。
  • 加强针后30天抗体水平上升(p=0.0486),且远高于第一剂和第二剂后。
  • 加强针后60天和90天抗体水平下降。
  • 曾感染医护人员的平均抗体水平高于未感染医护人员,源于自然感染和疫苗诱导免疫。
  • 14.7%的医护人员在加强针后感染奥密克戎变异株,但均无严重症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the present study, immunogenicity data in 61 vaccinated healthcare workers (HCWs) either infection naïve (naïve HCWs) or with infection of Delta and/or Omicron COVID-19 (experienced HCWs) were evaluated up to 270 days after the second dose of BNT162b2 vaccine and up to 90 days after a booster dose. A decrease in antibody levels at 270 days following administration of the second dose (p = 0.0335) was observed, although values did not fall below the positivity threshold (33.8 BAU/ml). After booster vaccination, antibody levels increased after 30 days (p = 0.0486), with much higher values than after first and second vaccination. Antibody levels then decreased at 60 and 90 days after the booster dose. A comparison between mean antibody levels of naïve and experienced HCWs revealed higher values in experienced HCWs, resulting from both natural and vaccination-induced immunity. A total of 14.7% of HCWs contracted the Omicron virus variant after the vaccine booster, although none showed severe symptoms. These results support that a booster dose results in a marked increase in antibody response that subsequently decreases over time.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vietri MT, D'Elia G, Caliendo G, et al. Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection. Vaccine. 2022. PMID: 36041940. doi:10.1016/j.vaccine.2022.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。